- Gold Hits $1,121, Barrick Chief Says Selloff Possible
- Foreclosures Fall Again But Improvement Likely Fleeting
- Highest State Foreclosure Rates
- Jobless, Wal-Mart to Drive Sentiment on Thursday
- Yuan Critics Want Obama to Keep Campaign Promise
- Dollar Trouble, Oil's Bubble Could Derail Recovery
- Hewlett-Packard to Acquire 3Com for $2.7 Billion in Cash
- AIG CEO: I Remain 'Totally Committed' to Firm
- CNN Anchor Lou Dobbs Says He is Leaving Network
- What to Expect From Disney Earnings?
- HP's Shot Across Cisco's Bow
- USC Football Blog Leads All-Access Space
- Clowning Around At Work
- Ahead of Earnings Disney Restructures Studio
- Nov. 11: Unusual Volume Leaders
- 3 'Clear Sailing' Mid-Caps For Investors: Strategist
- Intimate Apparel Sales Heating Up: Maidenform CEO
- A Day On The USS Harry S. Truman
MOST SHARED
- Hewlett-Packard to Acquire 3Com for $2.7 Billion in Cash
- How the Droid and Google Threaten the GPS Makers
- CNN Anchor Lou Dobbs Says He is Leaving Network
- Dollar Trouble, Oil's Bubble Could Derail Recovery
- USC Football Blog Leads All-Access Space
- Rising Jobless Biggest Threat to World Trade: WTO
- HPQ to Acquire 3Com
- Shopping for Answers
Text Size 
Abbott Labs said on Wednesday that third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic.
 |
The profit topped Wall Street forecasts, and revenue was in line with targets, a relief for investors on the heels of a disappointing sales report from rival diversified healthcare company Johnson & Johnson [JNJ
Loading...
()
]. Shares of Abbott [ABT
Loading...
()
] rose more than 2 percent as the company also nudged up its full-year profit forecast.
"It was a very solid quarter, and the most important thing is that Humira relieved concerns among investors that it might stall, from its previous rapid growth," said Morningstar analyst Damien Conover.
Conover said Humira's continued growth probably gave Abbott confidence to raise its 2009 profit forecast and that other aspects of the earnings report were much as expected.
Abbott said it had earned $1.48 billion, or 95 cents per share, up from $1.09 billion, or 69 cents per share, a year earlier. The results included a gain of $287 million from a previously announced settlement with Medtronic [MDT
Loading...
()
] over heart stent technology.
Excluding special items, the suburban Chicago company earned 92 cents per share. On that basis, analysts on average expected 90 cents, according to Thomson Reuters.
Sales rose 3.5 percent to $7.76 billion, in line with Wall Street expectations. Revenue would have risen 8.4 percent if not for the stronger dollar, which lowers the value of overseas sales.
Global prescription drug sales fell 1.6 percent to $4.1 billion, hurt by new generic forms of Abbott's Depakote anti-seizure medicine. But that represents an improvement over the 4.3 percent decline seen in the second quarter.
Humira sales rose 24 percent to $1.49 billion, about $30 million ahead of Wall Street expectations, according to the average estimate of five analysts polled by Thomson Reuters.
Abbott's nutritionals business continued to show strength, with sales rising 9.8 percent to $1.39 billion despite the stronger dollar. The company, which is steadily expanding this segment, announced in July it would pay $130 million for the nutrition businesses of Wockhardt Ltd, whose brands are sold in India.
The Wockhardt [WCKH
Loading...
()
] transaction is among five significant deals for Abbott this year, as the company aims to lessen its dependence on Humira for future earnings growth.
"The nutritionals business continues to do very well," said Conover. He speculated that Abbott was trying to "entrench" those products in fast-growing emerging markets and would later move aggressively to introduce lucrative prescription drugs there.
 |
Last month, Abbott said it planned to buy Solvay SA's [SOLB
Loading...
()
] pharmaceuticals unit for $6.6 billion in cash. The deal, the second-biggest in Abbott's history, would give it a number of new medicines in late stages of testing, including treatments for Parkinson's disease and other neurological conditions.
Analyst Tim Nelson of FAF Advisors in Minneapolis said Abbott's ability to meet sales targets and boost its earnings forecast would be a relief to investors.
Abbott shares, now trading at about 12 times expected 2010 per-share earnings, could rise later this year to a price-to-earnings ratio of 13 — catching up with larger rival Johnson & Johnson, Nelson said.
J&J shares fell 2.4 percent on Tuesday after the company posted weaker-than-expected revenue, on disappointing sales of its prescription drugs and heart stents.
Citing strong results so far this year, Abbott nudged up its full-year profit forecast to between $3.70 and $3.72 per share. Its earlier view was $3.65 to $3.70.
Abbott shares were up 2.1 percent at $50.70 in trading before the market opened.
- Bernard and Ruth Madoff's personal possessions will be auctioned this weekend. Click ahead to see.
- US real estate prices have fallen dramatically, but some places are still doing well. See the best-performing zip codes this year.
- An Italian cashmere maker aims to make profits while creating ideal conditions for his workers.
- Just in time for the holidays, the Triumph company of Japan offers the latest innovation in women’s undergarments.
- The real result of health care reform will be bloated government and higher deficits, says Larry Kudlow.
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
Data is a real-time snapshot *Data is delayed at least 15 minutes